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ABSTRACT 
 
Background 
 
The roll-out of antiretroviral drugs in South Africa started in March 2004. In Mopani 
district, a rural district of Limpopo Province, the roll-out programme commenced in 
October 2004. While many resources were invested in this program, no study has assessed 
the clinical outcomes in this rural district. In addition, most studies conducted in South 
Africa were conducted in urban and tertiary settings. Assessing clinical outcomes is 
important in determining whether the program is making the desired clinical difference in 
the lives of the patients and may serve as feedback into the program for quality 
improvement purposes.  
 
Methodology 
 
The study was a retrospective record review of patients who were initiated on 
antiretroviral (ARV) treatment between December 2007 and November 2008. A 
structured questionnaire was used to collect data from 124 patient’s files and data was 
collected up to November 2011. The data collected included patients’ socio-demographic 
characteristics, clinical outcomes (CD4 count, viral load, presence of opportunistic 
infections, adverse effects and hospital admissions recorded at 6, 12, 24 and 36 months), 
the number of patients who were still attending the ARV clinic at 36 months and the 
reasons why patients are no longer attending the clinic. Data was analysed with Epi-Info 
and STATA. 
 
Results 
 
Of the 124 patients, 69% were females, 28% males and 3% did not have their sex 
specified. The majority of the patients were between 30 and 49 years. There was a 
significant improvement in CD4 count and viral load between baseline and all time-
periods after the initiation of ARV treatment. The mean CD4 count at baseline was 128 
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cells/mm3; it increased to 310 cells/mm3 at 6 months, 380 cells/mm3 at 12 months and 470 
cells/mm3 at 24 months.  By 6 months, 67% of the patients had achieved viral suppression, 
but at 24 months, patients started having viral rebound. During the study, 20 patients fell 
pregnant and four patients fell pregnant twice. Overall, pregnant patients had a 
significantly higher viral load compared to non-pregnant patients (p-values = 0.015 at 6 
months, 0.002 at 12 months and 0.027 at 24 months). Seventy two percent of patients were 
retained in the program at 36 months. Of the 28% that were no longer attending the clinic, 
11.3% were transferred to other institutions, 6.5% were down referred to clinics, 3.2% 
died, 3.2% defaulted and 3.2% were lost to follow-up. 
 
Conclusion 
 
This study shows that good clinical outcomes can be achieved within an antiretroviral roll-
out program in a rural hospital. The biggest magnitude of clinical benefits was observed in 
the first six months after the initiation of ARV treatment with threats of viral rebound 
thereafter. There was good patient retention at 36 months after initiation of ARV treatment 
and a significant difference in viral load between pregnant and non-pregnant patients. The 
high rate of unplanned pregnancy signifies the need to place closer attention to family 
planning among female patients on antiretroviral treatment. 
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CHAPTER 1: INTRODUCTION 
 
Acquired Immunodeficiency Syndrome (AIDS) was first recognised as a new and 
distinct clinical entity in 1981.1 According to the Joint United Nations Programme on 
HIV/AIDS (UNAIDS) and World Health Organization (WHO), an estimated 39, 5 
million people were living with the Human Immunodeficiency Virus (HIV) by the end of 
2006. Of these, about 63% of all people, living with HIV resided in the Sub-Saharan 
region and 59% were women.2  
 
In South Africa, it was estimated that 0.8 % of the South African population was living 
with HIV in the early 1990s. Thereafter, the prevalence of HIV increased and several 
studies conducted on women attending antenatal clinics estimated that 30.2% pregnant 
women were living with HIV in 2005.3 In the general population however, an estimated   
10.8 % people over 2 years and 16.2% among the 15-49 years were living with HIV by 
the end of 2005. During this period, the prevalence of HIV in Limpopo Province was 8% 
and 8.8% in 2008.4 
 
There was a lot of controversy around HIV/AIDS policies in South Africa in 2000. This 
was  due to the reluctance of the then Minister of Health and the president of South Africa 
to adopt a public sector plan for treating HIV/AIDS with antiretroviral(ARV) treatment. 
They expressed doubts about whether HIV caused AIDS; they promoted good general 
nutrition, and discouraged antiretroviral therapy (ART) because of toxicity.  However, in 
2002, the South African cabinet affirmed the policy that “HIV causes AIDS” and in 
March 2003, the Treatment Action Campaign (TAC) laid a charge of manslaughter 
against the Health Minister for not rolling out ARVs; and against the Trade and Industry 
Minister for stopping production of generic ARVs in South Africa.5 In November 2003, 
the cabinet voted to make ARVs available in the public sector after having several 
deliberations with TAC.6 
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The roll-out of ARVs started in Gauteng Province in March 2004 followed by other 
provinces. By the end of December 2005, there were 204 ARV sites in the nine provinces 
and by the end of 2006, Limpopo Province had twenty-three operational ARV rollout 
sites, of which three were in Mopani District. 7 These three sites were in Letaba Hospital, 
C.N Phatudi Hospital (a district hospital which is about 20 km from Letaba Hospital) and 
Grace Mugodeni Health Centre (which is about 28 km from Letaba Hospital). In addition 
to the government sector, several private profit and non-profit centres offered ARVs.   
 
Although many resources were invested in the rollout of ARVs in South Africa, few 
studies have evaluated the clinical outcomes and the proportion of patients retained in the 
program. Studies that have done these were conducted in urban and tertiary settings, where 
clinical resources and support are better than in rural areas and the roll-out sites closer to 
academic centres. These urban studies demonstrated that patients who are started on ARVs 
could have good clinical outcomes (where the CD4 count increases, the viral load 
decreases, weight increases and the opportunistic infections decreases) and most had good 
patient retention.8,9,10,11,12 These are some of the indicators that were used to assess the 
effectiveness of ARVs. Whether these good clinical outcomes can be obtained in the rural 
setting where resources and clinical support are not easily available, is the focus of the 
current study.  The current study therefore aimed to determine the clinical outcomes and 
the extent of patient retention in the ARV roll-out program at Letaba hospital. It was hoped 
that the findings of this study would inform the development of interventions that can be 
used for clinical quality improvement at the ARV clinic at Letaba hospital and in similar 
rural ARV clinic settings.  
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CHAPTER 2: LITERATURE REVIEW 
  
2.1 Introduction 
 
This chapter presents the current knowledge about the clinical outcomes of ARV treatment 
programs and highlights gaps in knowledge that necessitated this study. This chapter is 
laid out in three sections: the process of literature search, presentation of the literature on 
ART and clinical outcomes, and conclusions from the literature review. 
 
2.2 Literature search 
 
The following Internet search engines were utilised to search for relevant literature: 
• PubMed ( The United States Library of Medicine) 
• Department of Health website 
• Cochrane Library 
• Google scholar  
• Google 
 
The Witwatersrand Medical Library was also used to search for available printed literature 
sources. Several search words used for the literature search included: “CD4 count”, “viral 
load”, “opportunistic infections”, ‘‘ART rollout’’, “monitoring and evaluation of ARV roll 
out sites”, “Global and South African HIV statistics”, “clinical outcomes of HAART”, 
“record keeping in ARV roll out sites”, “adherence”, “compliance”, “cost of HIV care”, 
‘‘effects of pregnancy on viral load and CD4 count’’,  and  “retention in ARV roll-out 
sites”. The literature search was conducted using several combinations of these search 
words and relevant articles were obtained and appraised for validity, importance, 
usefulness and applicability. The search yielded more than a thousand articles, of which 
about 150 with similar variables to the present study were selected. The abstracts were 
then used to further select articles that were relevant, reliable and those with similar 
methodology to the present study. Approximately 60 articles were finally selected and 
appraised.   
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Many studies were available on clinical outcomes, adherence and retention, but there were 
very few studies evaluating ARV roll-out programmes. Even fewer studies were conducted 
in rural areas in South Africa, and no studies were conducted in Limpopo Province.  
 
2.3 Presentation of Literature 
 
The literature will be laid out under the following topics: 
1. Clinical outcomes of ARV treatment 
2. Adherence to ARV treatment 
3. Patient retention in the ARV program 
4. ARV treatment roll-out programme 
5. Monitoring and Evaluation of the ARV treatment program 
 
2.3.1 Clinical outcomes of ARV treatment  
There are a number of studies in the literature on clinical outcomes of patients on ARV 
treatment. Most studies have reported on CD4 count, viral load, weight gain, presence of 
opportunistic infections and adverse effects, as key clinical outcomes of ARV 
treatment.8,10,11,12,13,14 The subsections that will follow will review literature on these 
outcomes of ARVs. 
 
2.3.1.1 CD4 count 
CD4 cells are a type of white blood cells that fight infections. 15 The CD4 count measures 
the number of CD4 cells/mm3 in the blood. HIV targets CD4 cells by binding to the 
surface of CD4 cells, then enters the CD4 cell and continues to replicate while inside, 
leading to the destruction of the CD4 cells. A normal CD4 count ranges from 600 to 1200 
cells/mm3.16 There are factors other than HIV that can affect the CD4 count; these include 
infections, time of the day, smoking, stress, sex (women tend to have a higher CD4 count 
than men by about 100 cells) and the laboratory used.17 Along with viral load, the CD4 
count helps in the assessment of the immune status of the patient, guides treatment and 
predicts the prognosis. CD4 is therefore a good clinical outcome measure.  
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Studies have shown a variation in the improvement of CD4 count results after the initiation 
of ARV. The average improvement ranged from 68 to 165 cells/mm3, the patient’s CD4 
count increased for all time periods but the biggest magnitude was in the first 6 months. 
After 6 months of ARV, the CD4 count increased at a slower rate. 8,13, 14,18 Studies that 
followed up patients for a longer duration and had a large number of patients tended to 
have higher mean CD4 rise as demonstrated by the studies conducted in South Africa, 
Rwanda and Malawi. 13,8,18,19,20 In a South African study conducted in Khayelitsha, mean 
CD4 increased from 95 cells/mm3 at baseline to 404 cells/mm3 at 32 months. The strength 
of the study was a large sample size of 929, completeness of data and the fact that patients 
were monitored closely and non-compliant patients were picked up early and given intense 
adherence counselling.19 While in the Cambodia study, the CD4 count increased from 11 
cells/mm3 at baseline to 274 cells/mm3 in 24 months. The patients had lower baseline CD4, 
implying that they had very sick patients. The intense education and counselling given to 
the patient might have contributed to the significant improvement in the CD4 count. In the 
Sanne study (2009), the baseline CD4 cell count was 87 cells/mm3   and after 6 months, the 
CD4 cell count was above 200 cells/mm3 in almost all the patients. The study had a large 
sample size of 7583, time-to-event data was collected prospectively and it was conducted 
in a well-resourced programme. Missing data was one of the limitations in the study.8 
 
In the beginning of ARV treatment rollout, doctors were the only category of health care 
professionals that were prescribing ART. Due to the shortage of doctors and the need to 
increase access for patients needing treatment, task shifting was introduced.13 The task of 
prescribing ARVs was shifted from doctors to nurses so that more patients can be treated. 
However, there was fear that the clinical outcomes of HIV care may be jeopardised by this 
task shifting. In a study evaluating Nurse-centred ART in Rwanda, the mean CD4 count of 
patients started on ARV treatment increased by between 79 and 128 cells/mm3.13 Though 
nurses managed the patients, the outcomes were good and comparable to centres where 
patients were managed by doctors. Even though the study had a large sample size and the 
nurses were given intense training; the selection of the sites, nurses and of the patients was 
not done randomly. There was selection bias as only centres that offered relatively 
favourable conditions like strong management and adequate staffing were selected.  The 
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positive results might have been influenced by these favourable conditions. This 
undermines the external validity of the study and the ability of the results to be generalised 
to the rest of the population where the conditions might not be favourable. This is an 
important consideration for rural settings, where there are poor resources. 
 
2.3.1.2 Viral load 
Viral load test is a quantitative measurement of HIV nucleic acid, reported as 
copies/mm3.The latest tests can measure values as low as 40-50 copies/mm3 (reported as 
undetectable) and as high as 1 million copies / mm, depending on the laboratory used.17 
There are no magic numbers for viral load and the goal of treatment is to reduce it to 
undetectable levels. The viral load provides important information that is used in 
combination with the CD4 cell count to monitor the status of HIV disease, to guide 
recommendations, to monitor the effects of ARV treatment and to predict the future course 
of HIV.16,21 Viral load is therefore another good clinical outcome measure. After the 
initiation of ARV treatment, the viral load is expected to drop and be undetectable by six 
months. 22 Studies have shown a varied response of viral load after the initiation of ARV 
treatment, with the percentage of patients who achieve an undetectable viral load by 12 
months ranging between 45 and 90%. 8,9,14,10,23,24 Even though patients achieved viral 
suppression after  initiation, there was a trend of increasing virological treatment failure 
with increasing duration on ARV treatment. 8,10 This was also demonstrated in a study 
conducted in Johannesburg, where good virological outcomes were achieved at the onset 
but subsequently, 9.4% had viral rebound within one year, 16.8% within two years and 
20.6% within three years. Studies that were conducted over a longer period, with larger 
sample size and used time-to-event demonstrated increasing virological failure with time.8 
Cross sectional studies conducted over a short period of time terminated before the viral 
rebound can be demonstrated and did not show this trend.  
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2.3.1.3 Weight gain 
Weight gain is another clinical outcome reported in a number of studies. There was 
significant mean weight gain ranging between 1.5 and 4.3 kg in the first six months after 
initiating ARV treatment. Beyond six months, there was a positive trend towards weight 
gain but the increases were not statistically significant. 11,13 Possible explanations provided 
for this increases are; after the initiation of ARV treatment, patients feel better and their 
appetite improves.  As the opportunistic infections decrease, the metabolic rate decreases - 
encouraging weight gain; ARV treatment also contributes to metabolic adverse effects, 
which include elevated cholesterol and triglycerides, insulin resistance and centripetal 
redistribution of body fat.16 
 
2.3.1.4 Opportunistic infections 
Opportunistic infections are infections that take advantage of the weak immune system.25 
There is a correlation between CD4 count and HIV-associated opportunistic infections. 
The type and severity of opportunistic infections that patients experience often depends on 
the level of the CD4 count, with certain HIV-associated diseases being common when the 
CD4 count reaches certain levels. Below is a summary of the correlation between 
opportunistic infections and CD4 count:10,25 
>500 cells/mm3 
•  Immunity is minimally affected   
• Recurrent vaginal candidiasis 
200- 500 cells/mm3 
• Pulmonary tuberculosis 
• Herpes zoster 
• Oropharyngeal candidiasis  
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< 200 cells/mm3 
• Pneumocystis jiroveci 
• Mucocutaneous herpes simplex 
• Cryptosporidium 
• Oesophageal candidiasis 
• Milliary/extrapulmonary tuberculosis 
<100 cells/mm3 
• Cerebral toxoplasmosis 
• Cryptococcal  meningitis 
<50 cells/mm3   
• Cytomegalovirus 
• Disseminated mycobacterium avium intracellulare (MAC) 
 
This correlation between opportunistic infections and CD4 count is used to decide on 
clinical prophylaxis to reduce the incidence and the severity of opportunistic infections. 
After the initiation of ARV treatment, the immune system recovers and the incidence of 
opportunistic infections decreases dramatically.10, 24, 25  
 
2.3.1.5 Adverse effects 
Adverse drug reaction is a broad term referring to an unwanted, uncomfortable or 
dangerous effect that a drug may have.16 Adverse effects are common in patients on 
ARVs. The percentage of patients found to have adverse effects ranged from 44% to 76% 
in the literature, with between 2.8 and 5.3% requiring a regimen change. 11,13,14 Dizziness, 
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peripheral neuropathy and rash were reported to be the most common side effects. Studies 
that were conducted over a longer period reported peripheral neuropathy as the commonest 
side effect, while those conducted over a shorter period reported dizziness, rash, headache 
and nausea/vomiting to be the most common.8,9,11,14 This might be because peripheral 
neuropathy manifests after patients have been on treatment for a longer period in contrast 
to dizziness, nausea/vomiting and headache, which manifests earlier and get better with 
time as the patient is accustomed to the drugs. The side effects can range from mild 
tolerable to life-threatening effects.  Symptomatic therapy can be given for some side 
effects, but if they get worse or become intolerable, drugs will need to be switched. For 
life- threatening side effects, all treatment will need to be interrupted and certain drugs 
should never be used on the same patient again.22 An article on the challenges of limited 
formulary states that toxicities to antiretroviral therapy make long-term adherence to 
therapy difficult for patients.26 The article further states that in resource-poor settings, 
where there are limited drug options, when and how to change therapy are especially 
difficult problems. A larger formulary is needed to allow changes and use of drugs that are 
less toxic because toxicities have the capacity to discourage patients, undermine adherence 
and reduce the effectiveness of ARVs in resource-poor nations.  
A study was conducted in Rwanda assessing the quality of life in HAART-treated HIV 
positive patients with body fat redistribution. The findings indicated that HAART-treated 
patients with body fat redistribution experienced lower quality of life than their HIV-
infected counterparts without body fat alterations.27 Therefore although the benefits of 
antiretroviral therapy cannot be underestimated, the psychological and social impact of the 
associated body fat changes cannot be ignored.27 Looking for side effects, explaining them 
to the patients and switching treatment early is important in enhancing compliance. The 
limitation of the study was the fact that the study was cross-sectional, conducted over one 
year with a once off interview on quality of life. Quality of life is subjective and may 
change over time. There are a number of factors that affect quality of life, poverty is one of 
them and this particular study was conducted in a poor community. 
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2.3.2 Adherence to ARV treatment 
 
As shown by the studies above, the introduction of ARV treatment yielded good clinical 
outcomes but patients tended to get viral rebound and treatment failure with time. It is 
important to investigate reasons for these in individuals as adherence is a very important 
predictor of undetectable viral load.28,29 There are a number of factors that influence 
adherence. Amongst others are cost, adverse effects, social, cultural and psychological 
influences. 42 The South African National Antiretroviral Treatment guidelines advises that 
adherence should be assessed by doing pill count at each visit with an adherence goal of 
>95% and re-adherence is to be offered to patients with an adherence of <80% and for 
patients who miss their clinic visits.22 This method is easy, but labour intense. The lay 
councillors can do the pill count and the doctor can review the results during consultation. 
Patients can be asked adherence questions and reasons for non-adherence. In the Van 
Oosterhout study, virological failure was associated with a positive response to non-
adherence. Two adherence questions pertaining to having missed a tablet a day before or a 
week before the clinic visit correlated with sub therapeutic nevirapine plasma levels. In 
this study, interviews conducted on side effects indicated that 76% of patients experienced 
side effects and 3% mentioned side effects as a reason for non-adherence.14 
 
2.3.3 Patient Retention 
 
Patient retention in the treatment program is important for patients on ARV treatment to 
achieve optimal clinical outcomes, to ensure continuation of treatment, to monitor side 
effects and to identify treatment failure. In a large systematic review conducted in 2007 on 
74,289 patients from resource-limited settings, it was estimated that about 50% of the 
patients initiated on ARV treatment were retained at 24 months. The analysis was updated 
in 2010 and the average retention was found to be 70% at 24 months and 64.8% at 36 
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months. In most studies, patients who were lost to follow up were not traced and there was 
a possibility that they might have continued on treatment at other treatment sites.30  
Two studies were conducted in South Africa  to investigate the reasons for loss to follow-
up (LTFU) amongst patients in an Antiretroviral treatment programs in Johannesburg.31,32 
In these two studies the researchers identified patients who were lost to follow-up through 
chart reviews and then attempted to trace patients in order to ascertain the reasons for 
LTFU. In both studies, large proportions of patients (55% and 35%) could not be traced 
because contact information was either missing or incorrect. Of those who were 
successfully traced, large proportions were found to have died (27% and 48%) or to have 
continued ARV treatment at other facilities (14% and 17%).  Those who were not in the 
above figures sighted reasons of financial difficulty (34% and 5%), lack of knowledge that 
ARV treatment is lifelong (percentage not reported), hospitalisation or illness (10% and 
0%) and interruption of treatment by the doctor (11 and 0.6%) as reasons to be unable to 
come for follow-up. In South Africa although the patients get treatment free, there is a cost 
on transportation. 
 
2.3.4 ARV treatment Roll-out.  
 
ARV roll-out is also a vital topic even though it was not included in the present study. The 
South African government endorsed the use and roll-out of free ARVs in public health 
facilities in August 2003 after many debates, a legal case and marches by Treatment 
Action Campaign (TAC). There was also a commitment made by the government to 
provide ARVs to over a million people with HIV/AIDS by early 2008.33 Even though 
ARV treatment roll-out started in March 2004; there has been a lot of delays and problems 
in accrediting public health facilities for ARV roll-out, providing appropriately trained 
health personnel and registering drugs. It is estimated that more than 330 000 deaths and 
about 35 000 infant HIV infections occurred between 2000 and 2005 due to HIV/AIDS 
denialism.34 However, there has been much progress but the target of putting 1 million 
people on ARVs was not met by the end of 2009. There are no accurate estimates of the 
number of people on ARV treatment but it is estimated that about 700 000 were receiving 
     12 
 
ARVs by 2009 and the number increased to 920 000 by 2010. There is a need to scale-up 
the number of people on treatment significantly in South Africa but this has serious cost 
implications because ARV drugs are expensive.  
A study was conducted in G.F Jooste Hospital, Cape Town, in 2005 to determine the cost 
of care for inpatients and outpatients at a dedicated antiretroviral referral unit, to identify 
key epidemiological cost drivers and to examine the associated clinical and outcome data. 
The study was a prospective costing study on 48 outpatient and 25 inpatients for a period 
of one month. The results showed that the incremental cost per outpatient was R1280, 00 
and R5802, 00 for inpatients. In summary, the study showed that the cost of providing 
secondary level care for on or immediately preceding ARV initiation can be significantly 
high.35 The study was conducted about seven years ago and the current cost is expected to 
be much higher than the figures shown. A proposal was made that the budget should be 
included in the governments strategic planning, so that the services can be expanded to 
meet current needs and to avoid overcrowding in secondary level health services. Studies 
that cost ARV services need to be conducted in the primary health care setting, especially 
given that nurse-initiated ARV services have been found to be effective and could reduce 
the cost. 
 
2.3.5 Monitoring and Evaluation of ARV roll-out programs 
 
A National Strategic Plan (NSP) 2007- 2011was developed in May 2006 in South Africa.36 
The plan identified 19 goals that are needed to reach the NSP’s aims. These were 
structured under four key priority areas (KPA). Key Priority Area 3 is about Research, 
Monitoring and Surveillance. The NSP 2007-2011 recognised monitoring and evaluation 
as an important policy and management tool. It is further said that national, provincial and 
district level indicators to monitor inputs, processes and outputs will be used to assess 
collective efforts. Some of the seven goals of Priority Area 3 that are relevant to this study 
are: 
1. Develop and implement the M&E framework with appropriate indicators. 
2. Create an enabling environment for research in support of the NSP. 
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3. Conduct regular surveillance.36  
Monitoring and Evaluation in HIV care and support is still new and the development of 
effective monitoring tools is in the early stages.37 A study was conducted in Malawi with 
the aim of describing the supervision, monitoring and evaluation strategies used to assess 
the delivery of antiretroviral therapy during a nationwide scale-up of treatment in Malawi. 
This study demonstrated the importance of early supervision for sites that are starting to 
deliver antiretroviral treatment, and showed the value of combining data collection with 
supervision.38 Without supervision, errors in data will not be identified and corrected. 
Making monitoring and supervisory visits to delivery sites was seen to be essential for 
tracking the national scale-up delivery of antiretroviral treatment.  Another study was 
conducted in Malawi, to assess the quality of data aggregated by antiretroviral treatment 
clinics. This study reported that 82, 000 patients were enrolled in its free National ART                                                                                                                             
programme.39 In comparison to South Africa there were approximately 460, 000 people on 
treatment by 2007.4 Data compiled by the Ministry of Health supervisory team was 
compared to the quarterly aggregate data for April to June 2006 compiled and reported by 
the ART facilities. The study also examined whether site characteristics such as facility- 
type, burden (maximum number of new patients the clinic can start on ARV treatment 
each month), length of time providing treatment and the number of data clerks were 
associated with complete and accurate data in site reports. The results of this study showed 
that 70% of the sites provided complete data for all six case-registration fields in the site 
report. The aggregates for the number starting ARVs because  of tuberculosis history and 
patient occupation were less likely to be complete with 24 -26%  of sites having 
incomplete data and 80% of the sites had complete data on outcomes. Several factors were 
associated with data quality. These included a higher burden (starting more patients each 
month), having dedicated clerks for record keeping, having a visit by a zonal ARV 
treatment  supervisor, location, having provided ARVs for a longer period of time and 
non- rural setting.39 
 
2.4 Conclusion  
Literature shows that after the initiation of ARV treatment, good clinical outcomes can be 
achieved as shown with the increase in CD4 count, a decrease in viral load, increase in 
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weight and the decrease in opportunistic infections. The biggest improvement in clinical 
outcomes occurs in the first 6 months.  Even though patients had good virological 
outcomes in the early stage, there was a trend of virological failure with time. Literature 
also suggest that ARV treatment programs have good patient retention. Currently available 
studies were conducted in well-resourced and mostly urban settings. The few studies 
conducted in resource poor settings were conducted outside of South Africa. To bridge this 
gap in knowledge, the current study therefore aims to determining the clinical outcomes in 
the anti-retroviral clinic, Letaba Hospital; a typical rural hospital in South Africa. 
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CHAPTER 3: METHODS 
 
3.1 Aim 
 
The aim of this study was to determine the clinical outcomes and the extent of patient 
retention in an antiretroviral roll-out programme at Letaba Hospital.  
 
3.2 Objectives 
a) To describe the socio-demographic characteristics of patients attending the 
antiretroviral clinic 
b) To determine the clinical outcomes of patients attending the ARV roll-out 
clinic at 6, 12, 24 and 36 months, with clinical outcomes defined as the CD4 
count, the viral load, the burden of opportunistic infections and the side effects 
of ARV treatment. 
c) To determine the outcomes of follow-up of patients initiated at the ARV 
rollout program, specified as: the proportions of patients retained in the 
program at 6, 12, 24, 36 months; the proportion that died; the proportion 
transferred to other facilities and the proportion lost to follow-up. 
d) To explore the relationships between selected patient characteristics and the 
specified clinical outcomes. 
 
3.3 METHODOLOGY 
3.3.1 Study Design  
The study was a retrospective, record review of patients’ medical records. 
3.3.2 Site of Study 
The study was conducted at Letaba Hospital, a level 2 hospital in Mopani District. The 
hospital is situated in a rural area, about 18km from Tzaneen town in the Greater Tzaneen 
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Municipality. As a referral hospital, it caters for the 1.1 million people who reside in the 
district. According to a community survey conducted by Statistics South Africa in 2007, 
the population of Limpopo Province was 5 238 286, of which 1 068 568 were in the 
Mopani District and 349 087 in the Greater Tzaneen Municipality.40 The hospital receives 
referrals from two immediate community health centres and 18 surrounding clinics. In 
addition, six district hospitals (Van Velden, Kgapane, C N Phatudi, Sekororo, Maphuta 
Malatji, Nkhensani Hospitals) and one specialised hospital (Evuxakeni Mental Hospital) 
refer patients to Letaba Hospital. The ART clinic is known as Nyeleti Clinic and it started 
operating in October 2004. By 2007, one thousand five hundred patients were attended at 
the clinic monthly, while five hundred patients were already initiated on ARV treatment. 
At the time of the study in 2007/8, the clinic operated with three professional nurses, one 
staff nurse, seven lay counsellors and two data capturers. One or two doctors from 
departments in the hospital are allocated to provide medical services at the clinic daily. 
 
3.3.3 Study Population 
 
All adult patients who received antiretroviral treatment at Nyeleti Clinic and were initiated 
at the clinic between December 2007 and November 2008 were eligible to be included in 
the study. The clinic statistics estimated the number of patients to have been registered at 
the clinic during the study period to be 687.  
 
3.3.4 Sample and Sampling method   
The minimum number of medical records required for the study was 124. This sample size 
was calculated with the help of a statistician based on the following formula. 
2
2
e
)p1(pZ
n
−
= ,where p is the prevalence of HIV in Limpopo Province(8.8% ),3  Z is the 
confidence interval which is 95%, e is the sampling error which is 5% and n in the  
required sample number.   
All patients who were enrolled at the clinic were entered into a register. A systematic 
sampling method was used to select every third file from the register. The first file was 
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randomly selected. If a sampled file did not meet the inclusion criteria, the next file was 
selected  and the sampling continued (every third file) until the required sample size was 
achieved.     
Inclusion criteria: 
• Patients who were 18 years and older. 
• Patients who were initiated on treatment at Letaba Hospital. 
Exclusion Criteria: 
• Patients who were referred from other sites. 
• Files not found 
 
3.3.5 Data Collection   
Information was extracted from files that met the selection criteria and recorded onto a 
data collection sheet. A coding system was used on the data collection sheet to enable the 
researcher to go back to the files for further clarity where necessary, and to avoid re-
selection of the same files. The data collection sheet was developed by the researcher 
guided by the study objectives and it included the following information: 
Section 1 – Patient’s socioeconomic demographics such as age, residential address, sex, 
race, level of education, employment and marital status.   
Section 2 - Clinical Outcomes (CD4 count, viral load, presence of opportunistic infections, 
hospital admission and adverse effects recorded at 6, 12, 24 and 36 months). 
Section 3 – Information about patient retention (Checked if the patient is still attending the 
clinic. If not, is patient transferred, down referred, defaulted, deceased or lost to follow-
up?). 
 
3.4 Pilot Study  
A pilot study was conducted at the ARV clinic of C.N Phatudi Hospital. This hospital is a 
district hospital in Mopani District, situated about 23 kilometres from Letaba Hospital. 
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Twenty-five patient’s files were used for the pilot study. The pilot study helped to test if 
the data collection sheet was effective in collecting the data required, check if the required 
data was available and if the study was feasible. The results of the pilot study were not 
included in this study. 
 
3.5 Analysis 
 
A statistician assisted with the analysis of the data. The data collected was entered into 
Epi-Info TM version 6. Descriptive statistics was done in which frequencies, means, 
proportions and percentages were determined. For further data analysis, data was imported 
into STATA version 9.0-computer software. 2x2 tables were used to compare groups using 
ANOVA, t-tests, Chi-squared test and Fisher-exact test where cell count were less than 
five. A comparison of the outcomes (CD4 count and viral load) was done for the following 
groups- sex (male v/s female), education level (none/primary, secondary and tertiary), 
employment (employed v/s unemployed), different age groups and for pregnant v/s non-
pregnant. Patient retention was estimated as the proportions of patients still attending the 
clinic at set times and reasons for no longer attending the clinic were also identified. 
Associations were tested for between socio-demographic variables and clinical outcomes.  
P-value <0.05 was considered as statistically significant. 
 
3.6 Ethical consideration 
 
The research protocol was approved by the Human Research and Ethics Committee at the 
University of Witwatersrand (Clearance certificate number M110485). Permission to 
conduct the study was granted by the Provincial Research Committee of Limpopo and 
Chief Executive Officer of Letaba Hospital. Patients were not directly involved as the 
research was a record review. Confidentiality of the data collected was maintained as the 
data collection sheet was anonymous, codes were used for identification and only the 
researcher, the supervisor and the statistician had access to the data. 
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CHAPTER 4: RESULTS  
 
4.0 Introduction 
 
The results are presented under the following headings: 
1) Socio-demographic characteristics 
2) Co-morbid diseases   
3) Clinical outcomes (CD4 count, viral load, presence of opportunistic infections 
and adverse effects)  
4) Patient retention 
5)  Associations between socio-demographic characteristics and clinical 
outcomes. 
 
4.1 Socio-demographic characteristics.  
Hundred and twenty-four patient’s files were sampled amongst those who presented at the 
clinic between December 2007 and November 2008. Due to missing information and 
incomplete documentation of certain information, “n” is not always equal to 124 in the 
results presented below. 
 
4.1.1 Sex distribution 
Of the 124 patient files sampled, 85 (69%) were females, 35 (28%) males while 4 (3%) did 
not have their sex specified.  Figure 1 below shows the sex distribution of the patients. 
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Figure 1: Sex distribution 
 
4.1.2 Age distribution 
The ages of the patients ranged between 21 and 72 years. The mean age was 41 years and 
about 2/3 were below 50 years of age. Only 5% were above the age of 60. As noted in 
figure 2 below, the majority of patients fall in the age groups of 30-49years.  
 
Figure 2: Age distribution 
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4.1.3 Race  
All the patients who were sampled were Black South Africans. The clinic sees 
predominantly African patients. 
 
4.1.4 Marital Status 
The majority of the patients 61 (49%) in the study were single, 41(33%) married, 7 (6%) 
were divorced, 6(5%) were widowed and 9 (7%) had their marital status unspecified. 
Figure 3 below shows the marital status distribution. 
 
 
Figure 3: Marital status distribution 
 
4.1.5 Employment status 
Out of the 124 patients sampled, the majority 69(56%) were unemployed, 15(12%) were 
employed and 40 (32%) were unspecified. Figure 4 below shows the employment status of 
the patients. 
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 Figure 4: Employment status 
 
4.1.6 Education level 
Twenty-seven (22%) patients had no education or only went up to primary school, 
35(28%) secondary school and 4 (3%) went up to tertiary. For a large number of patients 
58(47%), the education level was not specified. Table 1 below shows the education levels 
for the study participants. 
    Table 1: Education level 
Education level Frequency Percentage 
Unspecified 58 47% 
None/primary 27 22% 
Secondary 35 28% 
Tertiary 4 3% 
 
 
4.1.7 Distance between place of residence and the hospital 
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The majority of patients, 59 (47.6%) lived less than 10 km to the hospital while 40 (32%) 
lived between 10-20km and 25 (20%) lived more than 20km to the hospital. Figure 5 
below shows the distance from residence to the hospital. 
 
  
Figure 5: Distance from place of residence to hospital 
 
4.2 Co-morbidities 
Forty-two (34%) patients had co-morbidities, with 7 (16%) patients having more than one 
co-morbidity. Twenty female patients fell pregnant and four patients fell pregnant twice 
during the study period.  Table 2 below shows the frequency of co-morbidities. 
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Table 2: Frequency of co-morbidities 
Co-morbidity No. of patients  Cancer 1 
Pregnancy 20 Peptic Ulcer 
Disease 
1 
Arthritis 13 Depression 1 
Hypertension 5 Cardiac 1 
COPD 2 Obesity 1 
Diabetes 1 Epilepsy 1 
 
 
4.3 Drug Regimen at baseline, 6, 12, 24 and 36 months 
At baseline 120 (97%) patients were started on drug regimen 1a and only 4 (3%) were 
started on regimen 1b. At 6 months, regimens were changed for 5 (4%) patients due to 
intolerable side effects and for one patient (0.8%) who fell pregnant. At 12 months 
regimens were changed for 8 (7 %) patients, 12 (11 %) at 24 months and for 10 patients 
(12%) at 36 months. 
 
4.4 Clinical outcomes 
 
4.4.1 CD4 count 
Of the 124 patients files sampled only 119 CD4 count results (96%) were available at 
baseline, 102 (83%) at 6 months, 101 (87%) at 12 months and 78 (70%) were available at 
24 months. The mean CD4 count was 128 cells/mm3 at baseline; it increased to 310 
cells/mm3 at 6 months, 380 cells/mm3 at 12 months and 470 cells/mm3 at 24 months. At 
baseline, 110 (93%) of patients had a CD4 count of 200 cells/mm3 or less. From six 
     25 
 
months the majority of patients had CD4 counts of >200 cells/mm3. There was a 
statistically significant improvement with regard to CD4 count at baseline versus all other 
time periods (p <0.05).  When comparing CD4 count at 6 months with 12 months, and 12 
months with 24 months, the increase was not statistically significant but there was a 
positive trend. Table 3 below shows the CD4 count results at all time periods.  
Table 3: CD4 count  
 Baseline 
 
6 months 
 
12 months 
 
24 months 
<50 19 (16%) 2 (2%) 3 (3%) 2 (3%) 
50-100 27 (23%) 11 (11%) 4 (4%) 4 (5%) 
101-200 64 (54%) 16 (15%) 16 (16%) 7 (9%) 
  >200 9 (7%) 73 (71%) 78 (77%) 65 (83%) 
Mean CD4 128 310 380 470 
Total  no.(n) 119 102 101 78 
Baseline v/s 6 months (p<0.05); baseline v/s 12 months (p<0.005); baseline v/s 24 months 
(p<0.005)  
 
4.4.2 Viral load 
 
Of the 124 patients files sampled only 77 (62%) viral load results were available at 
baseline, 101(82%) at 6 months, 100 (86%) at 12 months and 79 (71%) at 24 months. The 
viral load results ranged from 0 to 1200000 copies/mm3. At baseline only 7% of patients 
had a viral load of <50 copies/mm3, the majority of patients (81%) had a viral load of more 
than 400 copies/mm3. The number of patients with viral load <50 copies/mm3 increased 
significantly to 67% at 6 months, 61% at 12 months and 63% at 24 months. Results of 
viral load are shown in table 4 below. 
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Table 4: Viral load  
 Baseline 
 
6 months 
 
12 months 
 
24 months 
 
<50 5 (7%) 68 (67%) 61 (61%) 50 (63%) 
50-400 9 (12%) 17 (17%) 18 (18%) 10 (13%) 
401-5000 20 (26%) 16 (16%) 12 (12%) 7 (9%) 
5000+ 43 (55%) - 9 (9%) 12 (15%) 
Total 77 101 100 79 
Baseline v/s 6 months (p<0.05); baseline v/s 12 months (p<0.005); baseline v/s 24 months 
(p<0.005) 
 
4.4.3 Weight gain 
 
There was significant weight gain between baseline and 6 months (p=0.0063). For the rest 
of the study period there was a positive trend but the increase was not statistically 
significant. Table 5 below shows the mean weight and p-values per time. 
 
Table 5: Weight gain  
 Mean +/- sd p-value 
Baseline 57.4 +/-13.9 Baseline  
6months 62.1+/-12.6 Baseline v/s 6months (0.0063) 
12months 62.3+/-12.3 6 months v/s 12months (0.91) 
24 months 63.3+-14.6 12 months v/s 24 months (0.61) 
 
4.4.4 Opportunistic infections 
At baseline 68 (58.4%) patients had opportunistic infections, the number decreased to 55 
(44%) at 6 months, 39 (31, 5%) at 12 months and 19 (15.3%) at 24 months. Twenty-nine 
(23.4%) patients had more than one opportunistic infection. Table 6 below shows the list 
of opportunistic infections and their frequencies during the study period.  
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Table 6: Description of opportunistic infections 
 0-6 months 
n=68 
6-12 months 
n=55 
12-24 months 
n=39 
24-36 months 
n=19 
Gastroenteritis 18% (12/68) 11% (6/55) 15% (6/39) 21% (4/19) 
Tuberculosis 28% (19/68) 20% (11/55) 5% (2/39) 5% (1/19) 
Oral thrush 31% (21/68) 4% (2/55) 15% (6/39) 5% (1/19) 
Skin rash 10% (7/68) 18% (10/55) 5% (2/39) 1% (2/19) 
Upper 
respiratory 
tract 
infections 
22% (15/68) 44% (24/55) 44% (17/39) 42% (8/19) 
Otitis media 3% (2/68) 7% (4/55) 3% (1/39) 5% (1/19) 
Lower 
respiratory 
tract 
infections 
3% (2/68) 2% (1/55) 15% (6/39) 5% (1/19) 
Meningitis - - 3% (1/39) 3% (1/39) 
 
4.4.5 Side-effects  
During the study period, 74(59%) patients experienced side-effects. By six months 21 
(16.9%) patients had side-effects, 46 (37%) by 12 months, 40 (32.2%) by 24 months and 
32(25.8%) by 36 months. The most common side effect was skin rash, manifesting in 52% 
of the patients who presented with side-effects at 6 months, 74% at 12 months, 38% at 24 
months and 41% at 36 months. The incidence of skin rash was highest during the 6-12 
months period, and then it started decreasing after 12 months. The second commonest side 
effect was peripheral neuropathy with 38% at 6 months, 59% at 12 months, 63% at 24 
months and 53% at 36 months. Peripheral neuropathy increased after six months, with the 
highest increase between 12-24 months. Three (8%) patients developed lactic acidosis at 
12-24 months during the entire study period. Table 7 below shows the frequency of side 
effects per time period.  
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Table 7: Commonest side effects 
 0-6 months 6-12 months 12-24 months 24-36 months 
Peripheral Neuropathy 38% (8/21) 59% (27/46) 63% (25/40) 53% (17/32) 
Skin Rash 52% (11/21) 74% (34/46) 38% (15/40) 41% (13/32) 
Gastrointestinal  - 7% (3/46) 8% (3/40) 9% (3/32) 
Lactic Acidosis - - 8% (3/40) - 
Dizziness 4% (1/21) 4% (2/46) - - 
Lipodystrophy - - 3% (1/40) 3% (1/32) 
 
 
4.4.6 Hospital admissions 
Nine (7.2%) patients were admitted to hospital during the entire study period. Three of 
these nine patients admitted were admitted twice. There were seven admissions during the 
0-6 months period, the admissions decreased to 4 during the 6-12 months and to 1 during 
12-24 months. 
  
4.5 Outcomes of follow up 
4.5.1: Patient retention 
At 6 months 123 (99%) of the 124 patients were retained in the program, 116 (93%) at 12 
months, 111 (90%) at 24 months and 85 (72%) at 36 months. Figure 6 below shows the 
number of patients retained per time period.   
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Figure 6: Number of patients retained per time period 
 
4.5.2: Reasons for dropping out of ARV programme 
Of the 33 (28%) patients that were no longer attending Nyeleti, 14(43%) were transferred 
to other institutions, 8 (24%) were down- referred to clinics, 4(12%) died, 4(12%) 
defaulted and 3(9%) were lost to follow-up. Figure 7 below shows the reasons for patients 
no longer attending the clinic 
Deceased
(4)12%
Defaulted
(4)12%
Down-referred
(8)24%
Lost to follow-
up
(3)9%
Transferred 
(14) 43%
 
Figure 7: Reasons for dropping out of the ARV programme 
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4.6 Association of socio-demographics and clinical outcomes. 
4.6.1 Association between CD4 count and age 
No significant difference was observed in relation to CD4 count and age at baseline 
(p=0.27), 6 months (p=0.72), 12 months (p=0.89) and 24 months (p=0.19). In all age 
groups the majority of patients had a CD4 count of 200 cells/mm3 and less at baseline and 
a CD4 >200 cells/mm3 at 6, 12 and 24 months. Table 8 below illustrates the association 
between CD4 count and age. 
 
Table 8: CD 4 count by age 
 Age (years)  
<30 30-49 50+ p-value 
Baseline 
<50 3 (19%) 14 (17%) 2 (9%) 
0.27 
50-100 6 (38%) 19 (24%) 2 (9%) 
101-200 7 (44%) 42 (52%) 15 (68%) 
>200 0 (0%) 6 (7%)   3 (14%) 
      
6 months 
<50 0 (0%) 2 (3%) 0 (0%) 
0.72 
50-100 1 (7%) 10 (14%) 0 (0%) 
101-200 3 (21%) 10 (14%) 3 (19%) 
>200 10 (72%) 50 (69%) 13 (81%) 
      
12 months 
<50 0 (0%) 3 (4%) 0 (0%) 
0.89 
50-100 1 (7%) 3 (4%) 0 (0%) 
101-200 3 (21%) 10 (15%) 3 (17%) 
>200 10 (72%) 53 (77%) 15 (83%) 
      
24 months 
<50 0 (0%) 2 (4%) 0 (0%) 
0.19 
50-100 1 (14%) 1 (2%) 2 (13%) 
101-200 1 (14%) 6 (11%) 0 (0%) 
>200 5 (71%) 46 (83%) 14 (87%) 
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4.6.2 Association between CD4 count and sex 
 
No significant difference was observed in relation to CD4 count and sex at baseline 
p=0.18,   6 months p=0.83, 12 months p=0.59 and 24 months p=0.23. In both sex groups 
the majority of patients had a CD4 count of 200 cells/mm3 and less at baseline and a CD4 
>200 cells/mm3 at 6, 12 and 24 months. Although not statistically significant, more 
proportions of women tended to have higher CD4 counts. Table 9 below illustrates the 
association between CD4 count and sex.           
 
Table 9: CD 4 count by sex 
 Gender  
Male Female p-value 
Baseline 
<50 9 (28%) 10 (12%) 
0.18 
50-100 8 (25%) 19 (23%) 
101-200 13 (41%) 48 (58%) 
>200 2 (6%) 6 (7%) 
     
6 months 
<50 1 (4%) 1 (1%) 
0.83 
50-100 3 (11%) 8 (11%) 
101-200 5 (18%) 11 (16%) 
>200 19 (68%) 51 (72%) 
     
12 months 
<50 1 (3%) 2 (3%) 
0.59 
50-100 1 (3%) 3 (4%) 
101-200 7 (24%) 9 (13%) 
>200 21 (70%) 55 (80%) 
     
24 months 
<50 2 (9%) 0 (0%) 
0.23 
50-100 1 (6%) 3 (6%) 
101-200 2 (9%) 5 (9%) 
>200 17 (77%) 45 (85%) 
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4.6.3 Association between CD4 count and level of education 
 
Education level was not significantly related to CD4 count at baseline (p=0.13), 6 months 
(p=0.24), 12 months (p=0.34) and 24 months (p=0.94). At baseline, the majority (>75%) 
of the patients had a  CD4 count below 200 cells/mm3 in all educational levels, while at 6, 
12 and 24 months the majority (70% or more) had a CD4 count of  above 200 cells/mm3 in 
all educational levels. Table 10 below shows the association between CD4 and education 
level. 
 
Table 10: CD4 count by education level 
 Educational Level  
None/Primary Secondary Tertiary p-value 
Baseline 
<50 4 (16%) 6 (18%) 2 (50%) 
0.13 
50-100 9 (36%) 9 (27%) 1 (25%) 
101-200 12 (48%) 15 (44%) 0 (0%) 
>200 0 (0%) 4 (12%) 1 (25%) 
      
6 months 
<50 0 (0%) 0 (0%) 1 (25%) 
0.24 
50-100 2 (9%) 1 (4%) 0 (0%) 
101-200 5 (22%) 5 (18%) 1 (25%) 
>200 16 (70%) 22 (79%) 2 (50%) 
      
12 months 
<50 0 (0%) 1 (3%) 0 (0%) 
0.34 
50-100 0 (0%) 1 (3%) 0 (0%) 
101-200 5 (25%) 2 (7%) 1 (25%) 
>200 15 (75%) 26 (87%) 3 (75%) 
      
24 months 
<50 1 (7%) 0 (0%) 0 (0%) 
0.94 
50-100 1 (7%) 1 (5%) 0 (0%) 
101-200 1 (7%) 2 (11%) 0 (0%) 
>200 12 (81%) 16 (84%) 4 (100%) 
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4.6.4 Association between CD4 count and employment status. 
No significant difference was observed in respect to CD4 count and employment status at 
baseline (p=0.2), 6 months (p=1.00), 12 months (p=0.4) and 24 months (p=0.23). Table 11 
shows the relationship between employment status and CD4 count. 
Table 11: CD 4 count by Employment Status 
 Employment Status  
Employed Unemployed p-value 
Baseline 
<50 3 (21%) 10 (15%) 
0.20 
50-100 2 (14%) 19 (29%) 
101-200 6 (43%) 33 (50%) 
>200 3 (21%) 4 (6%) 
     
6 months 
<50 0 (0%) 0 (0%) 
1.00 
50-100 1 (7%) 5 (9%) 
101-200 3 (21%) 11 (19%) 
>200 10 (71%) 41 (72%) 
     
12 months 
<50 0 (0%) 1 (1%) 
0.41 
50-100 0 (0%) 3 (5%) 
101-200 0 (0%) 9 (16%) 
>200 14 (100%) 45 (78%) 
     
24 months 
<50 1 (8%) 0 (0%) 
0.23 
50-100 0 (0%) 3 (7%) 
101-200 0 (0%) 4 (9%) 
>200 12 (92%) 37 (84%) 
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4.6.5 Association between viral load and age 
There was no statistically significant association between viral load and age at baseline. At 
baseline 85% of patients in the 50+ age group had a viral load of > 5000 copies/mm3 
compared to 55%  for age group 30-49 years and 31% for age group of < 30 years 
(p=0.09). However, there was a statistically significant association between viral load and 
age at 6 months, 83% of patients in the 50+ age group had a viral load of < 50copies/mm3, 
compared to 65%  for 30-49 years and 58% for the <30 age group (p=0.032). At 12 
months (p=0.13) and 24 months (p=0.48) there was no significant difference between viral 
load v/s age. Table 12 below shows the association between viral load and age. 
 
Table 12: Viral load by age 
 Age (years)  
<30 30-49 50+ p-value 
Baseline 
<50 1 (8%) 4 (8%) 0 (0%) 
0.09 
50-400 1 (8%) 8 (16%) 0 (0%) 
401-5000 7 (54%) 11 (22%) 2 (15%) 
>5000 4 (31%) 28 (55%) 11 (85%) 
      
6 months 
<50 7 (58%) 46 (65%) 15 (83%) 
0.032 
 
50-400 0 (0%) 16 (23%) 1 (6%) 
401-5000 5 (42%) 9 (13%) 2 (11%) 
>5000 0 (0%) 0 (0%) 0 (0%) 
      
12 months 
<50 7 (64%) 40 (57%) 14 (74%) 
0.13 
50-400 1 (9%) 16 (23%) 1 (5%) 
401-5000 0 (0%) 10 (14%) 2 (11%) 
>5000 3 (27%) 4 (6%) 2 (11%) 
      
24 months 
<50 3 (50%) 38 (66%) 9 (60%) 
0.48 
50-400 1 (17%) 6 (10%) 3 (20%) 
401-5000 0 (0%) 7 (12%) 0 (0%) 
>5000 2 (33%) 7 (12%) 3 (20%) 
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4.6.6 Association between viral load and sex 
 
There was no statistically significant association between viral load and sex at baseline 
(p=0.12), 6 months (p=0.82), 12 months (p=0.77) and 24 months (p=0.93). Even though 
the association was not statistically significant, a higher percentage of males tended to 
have viral loads > 5000 copies/mm3 compared to females. Table13 below shows the 
association between viral load and sex. 
 
Table 13: Viral load by sex 
 Male Female p-value 
Baseline 
<50 1 (4%) 4 (8%) 
0.12 
50-400 2 (9%) 7 (14%) 
401-5000 2 (9%) 16 (31%) 
>5000 18 (78%) 24 (47%) 
     
6 months 
<50 22 (73%) 44 (64%) 
0.82 
50-400 5 (17%) 12 (17%) 
401-5000 3 (10%) 13 (19%) 
>5000 0 (0%) 0 (0%) 
     
12 months 
<50 16 (59%) 43 (61%) 
0.77 
50-400 5 (19%) 13 (19%) 
401-5000 3 (11%) 9 (13%) 
>5000 3 (11%) 5 (7%) 
     
24 months 
<50 15 (63%) 34 (63%) 
0.93 
50-400 3 (13%) 7 (13%) 
401-5000 3 (12%) 4 (7%) 
>5000 3 (12%) 9 (17%) 
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4.6.7 Association between viral load and education 
 
There was no statistically significant association between viral load and level of education 
at baseline (p=1.00), 6 months (p=0.90), 12 months (p=0.83) and 24 months (p=0.13). For 
all levels of education, the majority of the patient had a viral load of more than 5000 at 
baseline and, at 6, 12, 24 months most patients had a viral load below 50 copies/mm3. 
Table 14 below demonstrates the association between viral load and level of education. 
Table 14: Viral load by level of education 
 Educational Level  
None/Primary Secondary Tertiary p-value 
Baseline 
<50 1 (6%) 1 (6%) 0 (0%) 
1.00 
50-400 2 (12%) 2 (12%) 0 (0%) 
401-5000 2 (12%) 2 (12%) 0 (0%) 
>5000 9 (53%) 8 (47%) 2 (67%) 
      
6 months 
<50 17 (74%) 21 (68%) 3 (100%) 
0.94 
50-400 4 (17%) 5 (16%) 0 (0%) 
401-5000 2 (9%) 5 (16%) 0 (0%) 
>5000 0 (0%) 0 (0%) 0 (0%) 
      
12 months 
<50 11 (55%) 16 (59%) 3 (100%) 
0.82 
50-400 4 (20%) 7 (26%) 0 (0%) 
401-5000 4 (20%) 2 (7%) 0 (0%) 
>5000 1 (5%) 2 (7%) 0 (0%) 
      
24 months 
<50 8 (53%) 15 (71%) 4 (100%) 
0.16 
50-400 4 (27%) 0 (0%) 0 (0%) 
401-5000 1 (7%) 1 (5%) 0 (0%) 
>5000 2 (13%) 5 (24%) 0 (0%) 
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4.6.8 Association between viral load and employment status 
There was no statistically significant association between viral load and employment 
status, with p-values of (p=0.38) at baseline, (p=0.90) 6 months, (p=0.23) 12 months, 
(p=0.60) at 24 months. In both employed and unemployed patients the majority had a viral 
load of >401 copies/mm3 at baseline and that < 50 copies/mm3 at 6, 12 and 24 months. 
Table 15 below shows the association between viral load and employment status. 
Table 15: Viral load by Employment Status 
 Employment Status  
Employed Unemployed p-value 
Baseline 
<50 0 (0%) 3 (7%) 
0.38 
50-400 2 (22%) 3 (7%) 
401-5000 3 (33%) 13 (28%) 
>5000 4 (44%) 27 (59%) 
     
6 months 
<50 10 (77%) 39 (67%) 
0.90 
50-400 2 (15%) 10 (17%) 
401-5000 1 (8%) 9 (16%) 
>5000 0 (0%) 0 (0%) 
     
12 months 
<50 9 (69%) 31 (67%) 
0.23 
50-400 1 (31%) 3 (15%) 
401-5000 0 (0%) 10 (14%) 
>5000 0 (0%) 5 (8%) 
     
24 months 
<50 9 (68%) 31 (67%) 
0.60 
50-400 1 (8%) 3 (7%) 
401-5000 2 (15%) 3 (7%) 
>5000 1 (8%) 9 (20%) 
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4.6.9 Association of viral load with pregnancy status. 
There was a statistically significant association between viral load of pregnant compared to 
non-pregnant women at 6 months (p=0.015), 12 months (p=0.002) and 24 months 
(p=0.027). Pregnant women were more significantly likely to have a higher viral load than 
non-pregnant women. Table 16 below shows the association of viral load for pregnant 
versus non- pregnant women. 
 
Table 16: Viral load for pregnant v/s non-pregnant 
 Pregnant  
No Yes p-value 
Baseline 
<50 4 (10%) 0 (0%) 
0.46 
50-400 7 (17%) 0 (0%) 
401-5000 12 (29%) 4 (40%) 
>5000 18 (44%) 6 (60%) 
     
6 months 
<50 35 (69%) 9 (53%) 
0.015 
50-400 11 (22%) 1 (6%) 
401-5000 5 (10%) 7 (41%) 
>5000 0 (0%) 0 (0%) 
     
12 months 
<50 38 (73%) 5 (29%) 
0.002 
50-400 9 (17%) 4 (24%) 
401-5000 4 (8%) 5 (29%) 
>5000 1 (2%) 3 (18%) 
     
24 months 
<50 29 (69%) 5 (42%) 
0.027 
50-400 3 (7%) 4 (33%) 
401-5000 2 (5%) 2 (17%) 
>5000 8 (19%) 1 (8%) 
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4.6.10 Association between “distance between place of residence and hospital” and 
patient retention. 
 
There was no statistically significant association between distance from the place of 
residence to the hospital and patient retention. Table 17 below shows the relationship 
between the distance to place of residence and the proportion of patient retained. 
 
Table 17: Association between distance and patient retention. 
Distance Not retained Retained P value 
<10 km 17 (52%) 38 (45%)  
0.46 10-20 km 8 (24%) 31 (37%) 
20+ km 8 (24%) 16 (19%) 
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CHAPTER 5: DISCUSSION 
 
5.0 Introduction 
 
This chapter discusses the results of the study, compares them to the literature and 
highlights the implications for clinical practice and public health. 
 
5.1 Participant sociodemographics 
   
The study was conducted in a rural area in Limpopo. The majority of patients in the study 
(69%) were females, compared to 28% males and 3% were unspecified. The age ranged 
from 21 to 72 years, with a mean of 41 years and the majority of patients were in age 
group 30-49 years. These findings are similar to a number of studies where the patients 
were predominantly female and the mean age of the participants was between 30 and 49 
years. 8,11,13,14,41 The findings are similar to the Mcphail and the Hudspeth studies, where 
the majority of patients were female and men presented at older ages and with more 
advanced disease.11,31  Efforts are therefore to be made by the government in getting men to 
seek help on their health more often and to do so early.  Late presentation in advanced 
disease states have implications for the overall prognosis and survival outcomes, especially 
given that several studies on reasons for loss to follow-up in South Africa have found that 
patients who were found to have died, had very low mean CD4 counts.20,31,42,43  .   
 
Most of the patients in the study were females in the working and child bearing age group 
(67%).  The majority of the patients (56%) were unemployed even though most were in 
the working age group. Thirty two percent were unspecified and only 12% were employed. 
This compares to the Sanne study where 56% of the patients were unemployed.8 The 
Sanne study was conducted in an urban area with a much larger sample size. Although the 
reasons for unemployment were not explored, HIV disease might be contributing to the 
high unemployment rate since patients may be dismissed because of absenteeism or they 
become too sick to continue working.  Those who are employed would also need to take 
time off from work to go for regular consultations, follow-up and collection of 
medications. This has a negative impact on the South African economy and some patients 
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lose salaries on days absent from work. In the present study, thirty two percent of the 
patient’s employment status was not specified, signifying poor record keeping. These 
unspecified data could have affected the results, as it was not included in the analysis.  
 
To further complicate matters, most of the patients in the study had a lower education 
level. Twenty two percent had no education while 28% went up to secondary school, only 
3% went up to tertiary level and 47% were unspecified. South Africa has a high 
unemployment rate and in 2008 the national unemployment rate was 22.7%.40 The lower 
the education level, the more difficult it will be to get employment. Those who get 
employment are more likely to do so in labor intense jobs which might pose a problem in 
patients who have ill health such as HIV disease. For a large number of patients, education 
level and employment status were not specified. This is in spite of the fact that the 
demographic form that is available in the patients file had space for the two variables. This 
poor record keeping needs to be addressed through training and supervision. There is a 
need for the staff members to understand the importance of good record keeping and the 
implications of poor records. Poor record keeping will also make it difficult for patients 
who are lost to follow-up to be traced. 
 
The majority of females were in the child bearing age group and 20 patients (23.5 %) fell 
pregnant during the study period. In addition to strengthening family planning methods 
among patients, it is important to strengthen PMTCT to decrease the number of HIV 
infections in babies born to mothers who are HIV positive.  It would be important to find 
out if the patients have disclosed their HIV status to their partners, if the partners have 
tested and if they are also on medication. Counseling needs to be strengthened, where 
condom use and safe sex should be stressed because unprotected sex will lead to re-
infections and treatment failure.  
 
On the question of the distance travelled to hospital, a large number of patients (47.6%) 
lived less than 10km to the hospital. Even though Letaba hospital is not a primary health 
care facility, a number of patients who qualify to be seen at primary health care are still 
attended to at Letaba hospital. It is one of the centers that started ARV roll out in 2004. It 
was followed by Grace Mugodeni health center in 2007 and the rest of the clinics started 
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from October 2010. With the devolution of ARV treatment to primary health care through 
NIMART (Nurse Initiated Management of Antiretroviral Treatment), patients are now 
initiated at primary health centers and those who are stable on treatment are down referred 
from Letaba hospital to their local clinics. This will also decrease the workload at the 
hospital and improve quality of care. Down referred patients will have better access to 
health care services as they will be treated at clinics in their villages. The problem of 
transportation will be eliminated for patients fit to walk because most clinics are within 
walking distance.  It will also be easier for primary care practitioners to trace patients who 
otherwise would have been classified as LTFU. 
 
5.2 Participant co-morbidities  
 
In the study 42 (34%) patients had co-morbidities. Seven (16%) patients had more than 
one co-morbidity. The most common co-morbidity was pregnancy. Twenty patients fell 
pregnant during the study period, with 4 patients falling pregnant twice. During counseling 
patients should be encouraged to inform the health workers if they plan to fall pregnant so 
that they are advised to do so when their health status is optimal and drug regimens 
changed appropriately. Five (4%) patients were hypertensive, 1(0.8%) diabetic and 
1(0.8%) had a cardiac problem. There are very few studies in the literature that reported on 
the prevalence of co-morbidities in patients on ARV treatment. The Reproductive Health 
and HIV Research Unit (RHRU) conducted a cross-sectional study where they reported 
similar results with the prevalence of hypertension between 2 and 12%, and diabetes at 
around 1%.44 With the advent of ARV treatment, the life expectancy of HIV positive 
individuals is improved and non-HIV related illnesses of the cardiovascular and renal 
systems are emerging. Nephropathy and cardiomyopathy can be complications of 
hypertension, diabetes and HIV. Several drugs in HIV management (for example- 
tenofovir and co-trimoxazole) are also associated with renal disease.45 Patients on ARV 
treatment who also have a chronic disease will be on multiple drugs and there is a risk of 
drug to drug interaction. Non-nucleoside reverse transcriptase inhibitors (NNRTIs) and 
Protease inhibitors (PI) are metabolized by the cytochrome P450 enzyme (cyt P450) 
system.  Drugs that induce or inhibit the cyt P450 enzymes may interfere with the 
metabolism of these drugs.  PI’s may also decrease the metabolism of the calcium channel 
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blockers, leading to increased serum concentrations which may increase risk of AV nodal 
blockade. HMG CoA reductase inhibitors used for the treatment of hyperlipidaemia 
compete with PI’s for cyt P450; this may increase the serum concentration of HMG CoA 
reductase inhibitors increasing the risk of myopathy.45,46 Patients with co-morbidities end 
up collecting all their chronic medication from the ARV site to avoid double trips to the 
hospital. If this is allowed to continue, the management of other chronic conditions should 
be done comprehensively according to guidelines. Drug interaction will be better 
monitored if patients collect all their chronic medication at the same site. The pill burden 
due to co-morbidities can also lead to poor adherence.47 An effort is to be made to simplify 
drug regimens as much as possible to improve adherence. 
 
5.3 Drug Regimen at baseline, 6, 12, 24 and 36 months 
At baseline 97% of the patients were started on Regimen 1a and 3% on regimen 1b. This is 
in line with the 2004 South African National Antiretroviral treatment Guidelines where 
Regimen 1a and 1b were first-line therapy for adults48 and also compares to the Brennan 
T.A and the Hudspeth studies where 89.4% and 92% of patients were started on regimen 
1a respectively.9,11 During the study period regimens were changed due to pregnancy, 
treatment failure and for intolerable side effects.  In total 36(29%) patients were changed 
regimens during the study period where 6 (5%) were changed to other regimens at 6 
months, 8 (7%) at 12 months, 12 (11%) at 24 months and 10 (12%) at 36 months.  
Seventeen patients were changed due to side effects, of which 12 were changed due to 
peripheral neuropathy.  By 6 months, 16.9% of the patient had side-effects. This increased 
to 37% at 12 months, 32.2% at 24 months and 25.8% at 36 months. The most common 
side effect was skin rash followed by peripheral neuropathy as shown in table 7. In the Van 
Oosterhout and the Sanne studies, peripheral neuropathy was the most common side effect 
followed by skin rash.8,14 During data collection in the present study, it was difficult to 
decide whether the rash was due to side effects or skin pathology due to opportunistic 
infections because in most cases the cause was not recorded by the examining doctor. Skin 
rash as a side effect might be overrated. Peripheral neuropathy is associated with the use of 
D4T and Didanosine (ddI).  All patients in this study were started on a regimen containing 
D4T and switched to AZT and TDF when the patient developed intolerable side-effects. In 
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most cases treatment-limiting toxicities occur early, but with D4T they continue to 
accumulate over time.49 New ART guidelines were published in 2010 and D4T is no 
longer a first line drug.22 This will significantly reduce the number of patients presenting 
with peripheral neuropathy as a side effect. It is of utmost importance to enquire about side 
effects, educate the patients and switch treatment early should the need arise.  
Seventeen patients were changed due to pregnancy while 3 (15%) patients were diagnosed 
after 12 weeks and their regimens were not changed. Teratogenic effects were reported 
with the use of efavirenz in animal studies.50 Recent studies have not confirmed the 
teratogenic effects in humans51, however caution should still be exercised especially in the 
first trimester and less teratogenic drugs such as nevirapine considered.  
 
5.4 Clinical outcomes 
 
At baseline 93% of patients had CD4 count of 200 cells/mm3 and below, the number 
decreased to 28% at 6 months, 23% at 12 months and 17% at 24 months. CD4 counts > 
200 cells/mm3 increased from 7% at baseline to 71% at 6 months, 77% at 12 months and 
83% at 24 months. There was an improvement with regards to the CD4 count between 
baseline and all time periods, with the biggest magnitude of change in the first 6 months 
after the initiation of ARV treatment. The CD4 count increased at a slower rate after 6 
months. The marked improvement in the first six months will encourage compliance and 
increase uptake in the ARV program. The mean CD4 count increased from 128 cells/mm3 
at baseline to 310 cells/mm3 at 6 months, 380 cells/mm3 at 12 months and 470 cells/mm3 
at 24 months. This compares to a number of studies where the mean CD4 count increased 
over time and is in line with the South African National Antiretroviral Guidelines where 
one of the goals of treatment is for the CD4 count to rise and remain above the baseline 
count.8,11,13,14,20,22,48,52 The patients in this study had good immunological outcomes that are 
comparable to those found in studies conducted in urban settings.9,10,12,19,49 There was also 
a significant improvement in viral load between baseline and all the time periods. The 
most significant improvement was between baseline and 6 months. By 6 months 84% of 
patients had suppressed viral load to </= 400, this compares to 90.8% in the Mcphail 
study.32  Sixteen percent of patients had virological failure at 6 months, the number 
increased to 22% at 12 months and 24% at 24 months.  This is viral rebound and the 
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percentage of patients with viral rebound usually increases over time. These were also the 
findings in the Sanne I.M and the Van Oosterhout studies.8,14.Viral rebound is associated 
with poor adherence in the early phases of ART initiation and with resistance in the later 
phases.19 Patients with viral rebound should be monitored closely and a trend observed 
over a period of time. This will increase the cost of treating the patient because more 
monitoring investigations will need to done to observe a trend and the patients might need 
to come more often for follow-up. Patients who have virological failure should be changed 
to second line treatment. This further limits the options should they fail on the second line 
drugs, as there are limited drug options in South Africa.    
 A major deficit was identified in this study, where at 24 months 19 (24%) patients had 
viral rebound with viral loads of >400 copies/mm3, only 2 patients were followed up and 
changed to regimen 2 (second line drugs).  Most of the patients were continued on a failing 
regimen without any intervention. This is caused by the fact that bloods are taken but 
results are not reviewed. This is a waste of resources, as bloods are sent to the laboratory to 
be processed and the hospital is billed. Expensive drugs are continued on patients with no 
clinical benefits. This amounts to clinical negligence and can result in poor adherence to 
treatment when patients realise that there is no improvement despite taking treatment. 
Maintaining patients on failing drug regimens also contributes to the development of drug 
resistance. 16 Studies have shown that if patients are monitored closely and adherence 
strengthened early in patients with viral rebound, fewer patients will have resistance.19A 
system needs to be introduced where red flags will compel clinicians to review results and 
take action whenever red flags are raised.  Haematological results were unavailable 
because the bloods were not taken for most of the patients. This is worrying because 
results are supposed to be used to assess the effectiveness of the drugs and to monitor 
adverse effects. This is one of the weaknesses in this clinic. Patient education can assist in 
solving this problem. If patients are educated about their disease, disease monitoring and 
treatment, they will be able to remind the health care provider about the blood tests and 
trigger the review of investigation results. A documentation chart with current results and 
dates for the next tests can also be utilised. The chart can be kept in the patients file and 
should be reviewed at each visit by the health care professional. 
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There was a significant mean weight gain of +/- 4.7 kg between baseline and 6 months. 
For the rest of the study period there was a positive trend but the increase was not 
statistically significant. The results are similar to those found in the Shumbuso and the 
Hudspeth studies where there was a significant weight gain of up to 4.3 kg in the first six 
months and no significant increase from 6 to 24 months.11,52 Weight gain in patients on 
ARV treatment is expected and it is very important for this weight gain to be monitored 
closely. As much as weight gain is a positive outcome in patients who are underweight, it 
can be a challenge if the patient gains a lot of weight and the Body Mass Index increases 
beyond 25 kg/m2. Obesity can reduce life expectancy, increase morbidity (due to diabetes 
and cardiovascular disease) and mortality.24  
The number of opportunistic infections found in this study decreased over time after the 
initiation of ARV treatment. The number of patients with opportunistic infections 
decreased from 68 (58.4%) at 0-6 months, to 55 (44%) at 6-12months, 39 (31.5%) at 12-
24months and 19(15.3%) at 24-36 months. This is one of the benefits of ARV treatment 
and these findings are similar to those that are reported in the literature, where the 
frequency of opportunistic infections decreases after the initiation of ARV treatment.53, 10 
After the initiation of ARV treatment, the CD4 count increases and the immune system 
recovers, reducing the incidence of the opportunistic infection and decreasing morbidity 
and mortality for the patient. As the CD4 continues to increase, certain prophylactic 
treatment will be stopped depending on the level of the CD4 count. This will also decrease 
the workload and the treatment cost. In the present study, the proportion of patients with 
upper respiratory infections (URTI) increased at 6-12 months and 12-24 months.  There is 
no logical explanation why this rate would increase during these periods. This might be 
due to the fact that data was collected from files and there was no set criterion for the 
diagnosis of URTI. The rate might therefore be exaggerated.   
During the entire study period, nine (7.2%) patients were admitted to hospital. Three of the 
nine patients were admitted twice. Most (7) of the admissions occurred during the  0-6 
months period, followed by 4 at 6-12 months, 1 at 12-24 months and none at 24-36 
months. The number of admissions was higher during the early stages of ARV treatment 
and it decreased over time on treatment. The finding is similar to that found in the 
Hudspeth study in which patients had fewer hospitalisations after ARV treatment 
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initiation. 11 In the early phases after ARV treatment initiation, the immune system is still 
weak and the body will still be susceptible to opportunistic infections. Patients with severe 
and life threatening infections may be admitted. As the immune system recovers and the 
body starts fighting infections, the incidence and the severity of opportunistic infections 
will decrease. This will also result in a decrease in the admission rate and further decrease 
in the cost of HIV management. 
 
5.5 Patient retention 
At 36 months, 85(72%) of the patients were still retained at the clinic. Of the 39 patients 
that were no longer attending the clinic, 14 (43%) were transferred to other institutions, 
8(24%) were down-referred to clinics, 4 (12%) died, 4 (12%) defaulted and 3 (9%) were 
lost to follow-up. Most of the patients that were no longer attending the clinic were 
accounted for and only 6.4% had defaulted or were lost to follow-up. The findings were 
similar to the Brennan A.T study (a cohort study of 4476 patients) in which at 24 months 
6.2% of the patients were lost to follow-up, 2.6% had died and 73.6% were retained.9 In 
the Shumbuso F study, 80% of the patients were retained at 24 months. Even though 
Letaba hospital is in a rural area with limited resources, patient retention is comparable to 
studies conducted in better resourced centers. The high rate of retention will increase the 
patient and financial burden at the clinic as there are also new patients who are initiated on 
treatment. There might also be emergence of non-HIV related illnesses. This will need to 
be considered and factored in during budget reviews.  
 
5.6 Relationships between socio-demographics, patient retention and clinical 
outcomes  
Statistical association was tested between the distance between patients’ residence and 
patient retention. There was no significant difference between distance from place of 
residence to the hospital and patient retention. The findings are different to those found in 
the literature. A review article by Geng E.H et al (2010) reported that distance to the clinic 
and transportation was found to be major barriers to patient retention in a variety of 
     48 
 
settings in Africa and Asia. In rural Uganda, 50% of the patients cited lack of 
transportation and 42% excessive distance resulting in clinic absenteeism.54 The high 
patient retention in the present study can be attributed to a number of factors including: 
good adherence counseling by the clinic staff, where patients are made to understand the 
importance of follow-up, positive staff attitude leading to high patient satisfaction rate 
(good patient- health worker relationship) and the temporary grant that was given to all 
patients with a CD4 < 200 cells/mm3 for 12 months. The temporary grant is given to 
patients when they are weak and unable to work. The grant enables them to hire private 
transport when they are too weak to use public transport and they are counseled and 
empowered on ideas to use the grant to start sustainable means of making a living when 
the grant lapses .    
Statistical association was tested between demographics and clinical outcomes. There was 
no significant association between CD4 count and age, sex, education level and 
employment status at all the time periods. There was no significant association between 
viral load and sex, education level and employment status. Even though there was no 
significant association between viral load and sex, a higher percentage of males tended to 
have a higher viral load.  In a number of studies, men were found to have had a higher 
viral load than females. 8,55 Men tend to access health care services late, when the disease 
is more advanced and the viral load higher. At baseline more than 80% of patients in the 
50+ age group had viral load >5000 copies/mm3 compared to 55% for age group 30-49 
years and 31% for age group <30 years. This may be due to the fact there is low index of 
suspicion for HIV in older people by both the patients and health care providers, leading to 
late presentation at advanced stage and late diagnosis. There was a significant difference in 
viral load between the different age groups at 6 months. More than 80% of the patients in 
the 50+ age group had an undetectable viral load, compared to 65% for the age group 30-
49 years and 58% for the < 30 age group. The patients in older age group had a 
significantly better viral load outcome than the younger age group at 6 months. This might 
be associated with good adherence, and might imply that older people had better adherence 
to treatment than younger ones.  
 There was an association between viral load and pregnancy. Non-pregnant women were 
more likely to have undetectable viral loads than those that fell pregnant, p=0.015 at 6 
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months, 12 months (p=0.002) and at 24 months (p=0.027). This is in contrast with what 
has been reported in the literature. In a study on the effects of pregnancy on 
immunological and virological outcomes of women on ARV treatment, there was no 
significant difference in the proportions of women with detectable viral load amongst 
those who fell pregnant and those who did not.56 In pregnancy, the immune function is 
suppressed in both HIV-infected and uninfected women.57 These changes have led to 
concern that the effects of pregnancy on HIV disease could accelerate the progression of 
the infection.  Follow-up studies showed that that there was no significant difference in the 
rate of acceleration of disease between the two groups.58 
 
5.7 Validity, reliability, bias and limitations 
Validity refers to the extent to which a measure actually measures what it is meant to 
measure.59  In ensuring validity in this study, the questionnaire was developed using 
information from the literature, guided by the supervisor and subjected to peer-reviewing 
by Family Physicians working in Letaba hospital. A pilot study was also conducted at C.N 
Phatudi hospital, a district hospital about 25 km from Letaba hospital, using twenty patient 
files. Appropriate corrections and adjustments were made to the questionnaire to ensure 
the validity and also to ensure that the research is feasible.  
The sample size was calculated with the help of a qualified statistician and a systematic 
sampling method was used. These processes ensured that the results may be generalized to 
the study population and that sampling bias was eliminated. Using a statistically adequate 
sample size also ensured that type II error was eliminated. 
Reliability refers to the degree of similarity of the information obtained when the 
measurement is repeated on the same subject or the same group.59 The explicitness of the 
research methods used enhanced reliability. 
The strength of the study was the fact that the record review covered a long period of time, 
enabling the trend in the clinical outcomes to be measured over time.   
The biggest limitation of this study was the fact that the study was a record review. The 
researcher relied on the availability of information in the files. It was impossible to get 
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information that was not recorded in the file. Even though 124 patient’s files were sampled 
at the beginning of the study, not all files contained all the information needed, resulting in 
missing data and therefore poor data quality.  
Since the information was collected as recorded in the file; there was no way that the 
researcher could ascertain that the information was true. This might have introduced 
information bias and affected the results also.   
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CHAPTER 6: CONCLUSION AND RECOMMENDATIONS 
 
6.1 Conclusion 
This study found that ARV roll-out program in a rural hospital can produce both good 
patient retention and clinical outcomes, shown by the increase in CD4 count, decrease in 
viral load, increase in weight and the decrease in opportunistic infections. These good 
clinical outcomes in this rural setting were most pronounced in the first six months after 
ARV initiation. There was however a tendency to losing viral suppression after 24 months 
of ARV therapy.  
Although there was good patient retention in this program 36 months after initiation of 
ART, unplanned pregnancies among female patients place them at risk for re-infection and 
virological failure. The finding that patients who fell pregnant during the study period had 
a higher viral load than those that did not indicates the need to give attention to family 
planning in the clinical management of patients on ARV treatment. 
 
6.2 Recommendations 
 
• A monitoring and evaluation programme which will ensure that guidelines and 
protocols are adhered to, should be developed to address the problem of health care 
providers not reviewing laboratory results. Such programs should identify priority 
indicators of clinical care and develop red-flags on non-compliance which persist 
on the system, until the problems are attended to.  
• Regular audits on quality of record keeping need to be conducted and feedback 
given to individual health care practitioners to assist them in improve their record 
keeping. 
• Patient education on family planning and safe sex, including condom use should be 
strengthened during clinic visits.   
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• Viral load testing should form part of PMCTC monitoring. 
• A system needs to be developed to help in tracing the patients who are lost to 
follow up. Full patient contact details are to be recorded in the patients file. These 
should include the residential address and two contact telephone numbers. Patients 
return dates should be recorded in a book and patients who do not turn-up for their 
appointments should be contacted telephonically. If patients do not present at the 
clinic after the call, the home-based careers in the villages should be contacted to 
make a follow-up, failing which the clinic social worker should be requested to do 
a home visit and report back to the clinic. 
• Given the risk of virological failure with time, support groups of people living with 
HIV disease should be encouraged to use the good clinical outcomes at the initial 
phase of ARV therapy to motivate patients to adhere strictly to treatment at later 
stage of treatment. Such encouragement can assist in addressing the inertia of not 
wanting to take treatment at later stages of therapy.    
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APPENDICES 
 
APPENDIX A: DATA COLLECTION SHEET 
                             
                 Code number  
  
 
 
 
 
Demographic Information: 
 
 
1. 
 
Age:  ________yrs. 
     
       
2. 
 Distance to Hospital: ___________km.     
 
 
    
3. Sex :            Male       Female     
    
4. Race:        African White   
 
 Indian Coloured   
      
5. Level of       No education                 Primary   
 
Education:  Secondary                Tertiary   
 
 
   
6. Marital   Single                 Divorced  Separated 
 Status  Married                Widowed   
7.    Employment       Employed           Unemployed            
 
Social Habits: 
  
     
1. 
 
Drink alcohol 
 
 Yes  No       
If yes how much   
______________ 
  
2. 
 
Smoking 
 
 Yes  No 
If yes how many 
  
 
 ______________   
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Medical Record to be checked for the following: 
 
  
      
 Baseline 6months 12months 24months 36 months 
Date 
     
Viral 
Load(copies/mm3) 
     
 CD4 
count(cells/mm3) 
     
Drug Regimen      
Weight (kg)    
  
Height(cm)    
  
    
  
Opportunistic 
Infections 
  
     
Oral thrush      
Tuberculosis      
Pneumonia      
Tumor/Cancer      
Skin Pathology      
Other      
      
Adverse effects   
Peripheral 
neuropathy 
     
Skin rash      
Stevens Johnson 
syndrome 
     
GIT  
 
    
Hematological  
 
    
Lactic acidosis      
Lipo dystrophy      
Others      
      
     
     
 Baseline 6months 12 months 24 months 36 months 
Are there any co-
morbid disorders 
 Yes   
  No 
 Yes   
  No 
 Yes   
  No 
 Yes   
  No 
 Yes   
  No 
If yes, which of 
the following 
     
Diabetes 
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Hypertension 
     
Epilepsy 
     
Asthma 
     
COPD  
     
Other 
     
 
     
     
Has the patient 
been admitted? 
 Yes  No  
    
If yes,  
     
Diagnosis 
     
Outcome of 
admission. 
     
Is the patient 
honoring follow-
up appointments? 
     
Is the patient 
compliant (pill 
count). 
     
  
 
Is the patient still attending Nyeleti Clinic  yes  no 
If no, give reason below      
    Deceased   
    Transferred   
    Down-referred             
Defaulted   
    Lost to follow-up  
    Unknown   
   Other________________________ 
 
 
 
 
 
 
 
 
 
 
 
 
 
     62 
 
                                                                                                                                                                               
APPENDIX B: ETHICS CLEARANCE CERTIFICATE 
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APPENDIX C: PERMISSION BY PROVINCIAL RESEARCH COMMITTEE OF 
LIMPOPO.  
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APPENDIX D: PERMISSION BY LETABA HOSPITAL MANAGEMENT 
  
 
 
 
 
 
